Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: A retrospective review

Zipes, 2006, ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, Circulation., 114, e385, 10.1161/CIRCULATIONAHA.106.178233 Blomström-Lundqvist, 2003, ACC/AHA/ ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias), Circulation., 108, 1871, 10.1161/01.CIR.0000091380.04100.84 Fuster, 2006, ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published correction appears in Circulation. 2007;116: e138], Circulation., 114, e257, 10.1161/CIRCULATIONAHA.106.177292 Goldschlager, 2007, A practical guide for clinicians who treat patients with amiodarone: 2007 [published correction appears in Heart Rhythm. 2007;4:1590], Heart Rhythm., 4, 1250, 10.1016/j.hrthm.2007.07.020 Tran, 2001, Practical approach to the use and monitoring of dofetilide therapy, Am J Health Syst Pharm., 58, 2050, 10.1093/ajhp/58.21.2050 Stelfox, 2004, Monitoring amiodarone's tox-icities: Recommendations, evidence, and clinical practice, Clin Pharmacol Ther., 75, 110, 10.1016/j.clpt.2003.09.010 Bickford, 2006, Adherence to the NASPE guideline for amiodarone monitoring at a medical university, J Manag Care Pharm., 12, 254, 10.18553/jmcp.2006.12.3.254 Burgess, 2006, Monitoring the use of amio- darone: Compliance with guidelines, Intern Med J., 36, 289, 10.1111/j.1445-5994.2006.01068.x Raebel, 2006, Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs, J Manag Care Pharm., 12, 656, 10.18553/jmcp.2006.12.8.656 Sanoski, 1998, Rationale, development, and clinical outcomes of a multidis-ciplinary amiodarone clinic, Pharmacotherapy., 18, 146S Goldschlager, 2000, Practical guidelines for clinicians who treat patients with amiodarone, Arch Intern Med., 160, 1741, 10.1001/archinte.160.12.1741 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron., 16, 31, 10.1159/000180580 Blouin, 1979, Tobramycin pharmacokinetics in morbidly obese patients, Clin Pharmacol Ther., 26, 508, 10.1002/cpt1979264508 Bauer, 1980, Amikacin pharmacokinetics in morbidly obese patients, Am J Hosp Pharm., 37, 519 Rigelsky, 2002, Hawthorn: Pharmacology and therapeutic uses, Am J Health Syst Pharm., 59, 417, 10.1093/ajhp/59.5.417